Strategic merger Jasper Therapeutics merged with Kira Pharma in July 2026 with a $132M syndicate led investment, signaling a broader platform and increased collaboration potential for sell-side partnerships and co-development opportunities.

Clinical programs Focus on novel antibody therapies targeting c-Kit for diseases such as CSU and LR-MDS, plus conditioning regimens for stem cell transplant, presenting multiple entry points for in-licensing, CRO collaborations, and material supply agreements.

Funding strength Significant funding status with total funding around $319M and annual revenue in the $10M–$25M range, suggesting capacity for strategic partnerships, milestone-driven deals, and shared risk ventures.

Leadership hires Recent senior-level appointments in clinical operations, regulatory affairs, quality, and medical leadership indicate maturation of operations and readiness for large-scale trials and regulatory submissions—opportunities for consulting, services, and alliance management.

Industry positioning Active engagement at healthcare conferences and a focus on oncology-immunology space with notable investors and a biotech veteran-led team position Jasper as a potential partner for co-development, equity investments, or platform collaborations in cellular therapies.